BACKGROUND: Standard first-line combination antiretroviral treatment (cART) against human immunodeficiency virus 1 (HIV-1) contains either a nonnucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r). Differences between these regimen types in the extent of the emergence of drug resistance on virological failure and the implications for further treatment options have rarely been assessed. METHODS: We investigated virological outcomes in patients from the Swiss HIV Cohort Study initiating cART between January 1, 1999, and December 31, 2005, with an unboosted PI, a PI/r, or an NNRTI and compared genotypic drug resistance patterns among these groups at treatment failure. RESULTS: A total of 489 patients started cART with a PI, 518 with a PI/r, and 805 with an NNRTI. A total of 177 virological failures were observed (108 [22%] PI failures, 24 [5%] PI/r failures, and 45 [6%] NNRTI failures). The failure rate was highest in the PI group (10.3 per 100 person-years; 95% confidence interval [CI], 8.5-12.4). No difference was seen between patients taking a PI/r (2.7; 95% CI, 1.8-4.0) and those taking an NNRTI (2.4; 95% CI, 1.8-3.3). Genotypic test results were available for 142 (80%) of the patients with a virological treatment failure. Resistance mutations were found in 84% (95% CI, 75%-92%) of patients taking a PI, 30% (95% CI, 12%-54%) of patients taking a PI/r, and 66% (95% CI, 49%-80%) of patients taking an NNRTI (P < .001). Multidrug resistance occurred almost exclusively as resistance against lamivudine-emtricitabine and the group-specific third drug and was observed in 17% (95% CI, 9%-26%) of patients taking a PI, 10% (95% CI, 0.1%-32%) of patients taking a PI/r, and 50% (95% CI, 33%-67%) of patients taking an NNRTI (P < .001). CONCLUSIONS: Regimens that contained a PI/r or an NNRTI exhibited similar potency as first-line regimens. However, the use of a PI/r led to less resistance in case of virological failure, preserving more drug options for the future.
BACKGROUND: Standard first-line combination antiretroviral treatment (cART) against human immunodeficiency virus 1 (HIV-1) contains either a nonnucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r). Differences between these regimen types in the extent of the emergence of drug resistance on virological failure and the implications for further treatment options have rarely been assessed. METHODS: We investigated virological outcomes in patients from the Swiss HIV Cohort Study initiating cART between January 1, 1999, and December 31, 2005, with an unboosted PI, a PI/r, or an NNRTI and compared genotypic drug resistance patterns among these groups at treatment failure. RESULTS: A total of 489 patients started cART with a PI, 518 with a PI/r, and 805 with an NNRTI. A total of 177 virological failures were observed (108 [22%] PI failures, 24 [5%] PI/r failures, and 45 [6%] NNRTI failures). The failure rate was highest in the PI group (10.3 per 100 person-years; 95% confidence interval [CI], 8.5-12.4). No difference was seen between patients taking a PI/r (2.7; 95% CI, 1.8-4.0) and those taking an NNRTI (2.4; 95% CI, 1.8-3.3). Genotypic test results were available for 142 (80%) of the patients with a virological treatment failure. Resistance mutations were found in 84% (95% CI, 75%-92%) of patients taking a PI, 30% (95% CI, 12%-54%) of patients taking a PI/r, and 66% (95% CI, 49%-80%) of patients taking an NNRTI (P < .001). Multidrug resistance occurred almost exclusively as resistance against lamivudine-emtricitabine and the group-specific third drug and was observed in 17% (95% CI, 9%-26%) of patients taking a PI, 10% (95% CI, 0.1%-32%) of patients taking a PI/r, and 50% (95% CI, 33%-67%) of patients taking an NNRTI (P < .001). CONCLUSIONS: Regimens that contained a PI/r or an NNRTI exhibited similar potency as first-line regimens. However, the use of a PI/r led to less resistance in case of virological failure, preserving more drug options for the future.
Authors: Regina B Osih; Patrick Taffé; Martin Rickenbach; Angèle Gayet-Ageron; Luigia Elzi; Christoph Fux; Milos Opravil; Enos Bernasconi; Patrick Schmid; Huldrych F Günthard; Matthias Cavassini Journal: AIDS Res Hum Retroviruses Date: 2010-10-07 Impact factor: 2.205
Authors: Alison G Abraham; Bryan Lau; Steven Deeks; Richard D Moore; Jinbing Zhang; Joseph Eron; Richard Harrigan; M John Gill; Mari Kitahata; Marina Klein; Sonia Napravnik; Anita Rachlis; Benigno Rodriguez; Sean Rourke; Constance Benson; Ron Bosch; Ann Collier; Kelly Gebo; James Goedert; Robert Hogg; Michael Horberg; Lisa Jacobson; Amy Justice; Greg Kirk; Jeff Martin; Rosemary McKaig; Michael Silverberg; Timothy Sterling; Jennifer Thorne; James Willig; Stephen J Gange Journal: Am J Epidemiol Date: 2011-08-03 Impact factor: 4.897
Authors: Alexandra U Scherrer; Viktor von Wyl; Beda Joos; Thomas Klimkait; Philippe Bürgisser; Sabine Yerly; Jürg Böni; Bruno Ledergerber; Huldrych F Günthard Journal: J Infect Dis Date: 2011-02-01 Impact factor: 5.226
Authors: Christa R Nevin; Jiatao Ye; Inmaculada Aban; Michael J Mugavero; David Jackson; Hui-Yi Lin; Jeroan Allison; James L Raper; Michael S Saag; James H Willig Journal: AIDS Res Hum Retroviruses Date: 2011-03-21 Impact factor: 2.205
Authors: Viktor von Wyl; Valentina Cambiano; Michael R Jordan; Silvia Bertagnolio; Alec Miners; Deenan Pillay; Jens Lundgren; Andrew N Phillips Journal: PLoS One Date: 2012-08-08 Impact factor: 3.240
Authors: Pamina M Gorbach; Lydia N Drumright; Marjan Javanbakht; Sergei L Pond; Christopher H Woelk; Eric S Daar; Susan J Little Journal: J Acquir Immune Defic Syndr Date: 2008-04-15 Impact factor: 3.731
Authors: Samuel Alizon; Viktor von Wyl; Tanja Stadler; Roger D Kouyos; Sabine Yerly; Bernard Hirschel; Jürg Böni; Cyril Shah; Thomas Klimkait; Hansjakob Furrer; Andri Rauch; Pietro L Vernazza; Enos Bernasconi; Manuel Battegay; Philippe Bürgisser; Amalio Telenti; Huldrych F Günthard; Sebastian Bonhoeffer Journal: PLoS Pathog Date: 2010-09-30 Impact factor: 6.823
Authors: Adrian Schmid; Sara Gianella; Viktor von Wyl; Karin J Metzner; Alexandra U Scherrer; Barbara Niederöst; Claudia F Althaus; Philip Rieder; Christina Grube; Beda Joos; Rainer Weber; Marek Fischer; Huldrych F Günthard Journal: PLoS One Date: 2010-10-12 Impact factor: 3.240